Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.

Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R Di Nicola, Antonio Foti, Vittoria G Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R Mercuri, Mario Valenti
{"title":"Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.","authors":"Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R Di Nicola, Antonio Foti, Vittoria G Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R Mercuri, Mario Valenti","doi":"10.1080/09546634.2024.2351489","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.</p><p><strong>Objective: </strong>to evaluate the efficacy of tralokinumab in AD patients with genital involvement.</p><p><strong>Methods: </strong>Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.</p><p><strong>Results: </strong>out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.</p><p><strong>Conclusion: </strong>despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2351489"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2351489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.

Objective: to evaluate the efficacy of tralokinumab in AD patients with genital involvement.

Methods: Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.

Results: out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.

Conclusion: despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.

成功使用曲妥珠单抗治疗生殖器特应性皮炎。
背景:特应性皮炎(AD)的生殖器受累会对患者的生活质量产生重大影响。目的:评估曲妥珠单抗对伴有生殖器受累的特应性皮炎患者的疗效:方法:对接受曲妥珠单抗治疗的中度/重度AD和生殖器受累的成人患者进行分析。主要终点是第16周时的EASI、DLQI、PP-NRS、生殖器IGA(g-IGA)和生殖器瘙痒(GI)。结果:在接受曲妥珠单抗治疗的48名中度/重度AD患者中,有12名患者(25%)出现生殖器受累。7名患者报告生殖器部位瘙痒(58%),但没有人报告有生殖器感染病史。T0时的中位评分为EASI 17.5分、PP-NRS 8分和DLQI 14分。治疗 16 周后,我们观察到 EASI 中位数为 3,PP-NRS 中位数为 1,DLQI 中位数为 1。 最后,在生殖器反应方面,治疗 16 周后,我们观察到 GI 和 g-IGA 平均得分出现了统计学意义上的显著下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信